Dalfampridine (4-AP extended release) Treatment Report

Category: Prescription Drugs

Most Popular Types: Ampyra

false

See also: Fampridine (4-AP immediate release)

What is Dalfampridine (4-AP extended release)?

An example of Dalfampridine (4-AP extended release)

Dalfampridine, is an extended release formulation of 4-aminopyridine or 4-AP. It is a potassium channel blocker that is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). Dalfampridine was previously called Fampridine-SR during clinical trials.

Reported Purpose & Perceived Effectiveness

Reasons and Perceived effectiveness
Perceived Effectiveness
Purpose # of patients # of patients with evaluations
Major
Moderate
Slight
None
Can’t tell
672 173 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
245 129 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
165 77 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
33 12 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none
31 13 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
24 15 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell

See all 743 patients currently taking Dalfampridine (4-AP extended release)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
24
Moderate
38
Mild
68
None
206

Commonly reported side effects, conditions, and hospitalizations associated with Dalfampridine (4-AP extended release)

21
16
11
9
7
6
See all 92 reported side effects See top 6 reported side effects

Reported Dosages

Frequently reported dosages based on patients currently taking Dalfampridine (4-AP extended release). See all 49 dosages

  1 mg daily 2 tablet(s) daily 2 other daily 2 mg daily 5 mg daily 10 mg daily 15 mg daily 20 mg daily 30 mg daily 40 mg daily
  11 Number of Patients: 11 9 Number of Patients: 9 17 Number of Patients: 17 26 Number of Patients: 26 10 Number of Patients: 10 177 Number of Patients: 177 14 Number of Patients: 14 386 Number of Patients: 386 25 Number of Patients: 25 19 Number of Patients: 19  

Reported Stop Reasons

Why Patients Stopped Taking Dalfampridine (4-AP extended release) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 128   Did not seem to work: 47%
Side effects too severe 71   Side effects too severe: 26%
Other 54   Other: 20%
Doctor's advice 36   Doctor's advice: 13%
Expense 32   Expense: 12%
Change in health plan coverage 12   Change in health plan coverage: 4%
Course of treatment ended 11   Course of treatment ended: 4%
Not indicated 7   Not indicated: 3%
Personal research 6   Personal research: 2%

See all 256 patients who’ve stopped taking Dalfampridine (4-AP extended release)

Currently Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Dalfampridine (4-AP extended release)

Always
268 80%
Usually
49 15%
Sometimes
5 1%
Never
14 4%

Burden

Difficulty being on treatment

Burden of Dalfampridine (4-AP extended release)

Very
6 2%
Somewhat
14 4%
A little
44 13%
Not at all
272 81%

Cost

Paid out of pocket

Cost of Dalfampridine (4-AP extended release)

$200+
15 6%
$100-199
16 6%
$50-99
54 20%
$25-49
96 36%
< $25
87 32%

Sort by: Helpfulness | Most Recent

53 patient evaluations for Dalfampridine (4-AP extended release)

Purposes: MS (Multiple Sclerosis) and Improve mobility (Started Jul 14, 2010)
Date Dosage MS (Multiple Sclerosis) Perceived effectiveness Improve mobility Perceived effectiveness Side Effects Adherence Burden
Jun 01, 2013 20 mg Daily Led_efficacy_3Led_efficacy_3Led_efficacy_3Led_defaultModerate Led_efficacy_4Led_efficacy_4Led_efficacy_4Led_efficacy_4Major NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Jul 11, 2010   Led_efficacy_3Led_efficacy_3Led_efficacy_3Led_defaultModerate NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Date
Jun 01, 2013
Advice & Tips
It must be working. My last Timed25 Foot Walk was 4 sweconds better than previous. 21 seconds vs 25 seconds. Ibelieve that the LDN is helping the Ampyra work better
Cost
< $25 monthly
Date
Jul 11, 2010
Advice & Tips
everyone says I am much more alert, possitive since beginning this treatment
Cost
$25-49 monthly
  • Icon_thumb_off 0 helpful marks
Purpose: MS (Multiple Sclerosis) (Started May 15, 2010)
Date Dosage Perceived effectiveness Side Effects Adherence Burden
May 15, 2013 10 mg Daily Led_efficacy_2Led_efficacy_2Led_defaultLed_defaultSlight NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
  • Icon_thumb_off 0 helpful marks
Purposes: Walking problems and Fatigue (Started Oct 12, 2012)
Date Dosage Walking problems Perceived effectiveness Fatigue Perceived effectiveness Side Effects Adherence Burden
Feb 17, 2013 20 mg Daily Led_efficacy_3Led_efficacy_3Led_efficacy_3Led_defaultModerate ModerateModerateModerateModerateModerate AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Jan 28, 2013 20 mg Daily Led_efficacy_3Led_efficacy_3Led_efficacy_3Led_defaultModerate Led_efficacy_1Led_defaultLed_defaultLed_defaultNone MildMildMildMildMild AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Jan 22, 2013 20 mg Daily Led_efficacy_2Led_efficacy_2Led_defaultLed_defaultSlight Led_efficacy_1Led_defaultLed_defaultLed_defaultNone NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Date
Feb 17, 2013
Advice & Tips
I stopped taking Amprya because of an unrelated stomach ailment, which temporarily stopped all my oral medications. When I started taking orals meds again, I opted to skip the Ampyra as an experiment because . . . I spent several years learning to manage my secondary fatigue, which (I learned) is heavily connected to the use of my legs. In other words, when I don't use my legs (even when I can), I avoid substantial fatigue. So I've leaned using my legs is like driving an electric car with defective batteries and no energy gauge. Taking Ampyra is like installing better batteries (i.e., I walk better), but they are a different size, so my previous sense for running out of energy is all wrong. Not only do I run out of energy suddenly and unexpectedly, but the recharge time is longer. So . . . do I stay off Ampyra and live like I got used to? Or do I take Ampyra to walk better, but work to become accustomed to a new internal energy gauge? ahhh heck, this is MS, we're used to working to become used to constantly changing new normals :) I'll go back on it. Thanks for listening.
Cost
< $25 monthly
Date
Jan 28, 2013
Advice & Tips
I've been taking Ampyra for about 4 months, now. Its effects appeared slowly and gradually. I asked my doc last week about stopping it because I didn't think it was helping much, even though my PT scored my walking better (no longer a fall risk). He said he'd rather I just skip some doses to see; so I did. I started noticing a difference within a few hours of missing a dose. After skipping two doses in a row then falling, I started taking it again. I haven't fallen since starting Ampyra; my balance is definitely better with it. So are my bowels; mine have been mushy and frequent for ages; taking fiber helped, but with Ampyra my bowels are near normal again without the extra fiber (the constipation side effect of Ampyra seems to be helping me).
Cost
< $25 monthly
Date
Jan 22, 2013
Advice & Tips
Firmer Stools is an unexpected positive effect. My wife and PT both say my walking is better since I started taking Ampyra. I do notice improvement but only very slight. Without Ampyra my walking ability gradually deteriorates the more I walk. With Ampyra, my walking ability stays stable while I walk, but then suddenly gives out, and my legs feel like their veins are full of diluted menthol. So Ampyra helps make my walking better while I'm walking, but it does not help me walk longer. Is it worth taking? I haven't decided yet.
Cost
< $25 monthly
  • Icon_thumb_off 0 helpful marks
1 2 3 4 5 6 ... 18    You are at the first page First There is no previous page Prev | Next Go to the next page Last Go to the last page 

Last updated: